The publication is a positive scientific milestone but does not alter the clinical development timeline or financial position. Monitor for initiation of the Phase 1/2 TNBC trial and any subsequent data readouts.
Price Chart
Executive Summary
Telomir Pharmaceuticals announced a peer-reviewed publication of preclinical data for Telomir-Zn in a zebrafish model of Type 2 diabetes, showing dose-dependent improvements in glucose homeostasis and insulin resistance. The publication adds scientific validation but does not change the near-term clinical or financial outlook.
Key Facts
- Second peer-reviewed publication on Telomir-Zn in 2026
- Preclinical data in zebrafish model of Type 2 diabetes showed HOMA-IR decline from ~10-12 to ~3 after 14 days
- Telomir-Zn has FDA IND clearance for Phase 1/2 trial in triple-negative breast cancer (TELO-001)
- Company is clinical-stage with no approved products or reported revenue
Financial Impact
No financial data provided; preclinical publication does not directly impact financials
Risk Factors
- Preclinical results in zebrafish may not translate to human clinical outcomes
- Company has no revenue and relies on financing to fund operations
- Phase 1/2 trial carries inherent risk of failure or delays
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-028614 |
| Exhibit: ex99-1.htm | 0001493152-26-028614 |
| Document: 0001493152-26-028614-index-headers.html | 0001493152-26-028614 |
| Document: 0001493152-26-028614-index.html | 0001493152-26-028614 |
| Document: 0001493152-26-028614.txt | 0001493152-26-028614 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $1.20 | awaiting T+20 | — | $0.9990 (−16.75%) |
Sep 17, 2026 5w ago | 8-K | $1.12 $1.05 | ▼ −6.25% | ▼ −7.46% | $0.9990 (−10.80%) |
Sep 17, 2026 5w ago | Press Release | $1.12 $1.05 | ▼ −6.25% | ▼ −7.71% | $0.9990 (−10.80%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $1.10 | ▼ −5.98% | ▼ −8.25% | $0.9990 (−14.62%) |
Aug 19, 2026 9w ago | DEFA14A | $1.17 $1.12 | ▼ −4.27% | ▼ −2.32% | $0.9990 (−14.62%) |
Aug 10, 2026 11w ago | 8-K | $1.17 $1.19 | ▲ +1.71% | ▲ +2.62% | $0.9990 (−14.62%) |
Jun 15, 2026 19w ago | 8-K | $1.29 $1.24 | ▼ −3.88% | ▼ −3.13% | $0.9990 (−22.56%) |
Jun 8, 2026 20w ago | 8-K | $1.21 $1.24 | ▲ +2.48% | ▲ +1.03% | $0.9990 (−17.44%) |
Apr 24, 2026 26w ago | 8-K | $1.40 $1.30 | ▼ −7.14% | ▼ −11.17% | $0.9990 (−28.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers